Category Archives: Global News Feed


Stem Cell Clinic > Global News Feed

Alkeus Pharmaceuticals Announces Results from the SAGA Study of Oral Gildeuretinol in Patients with Geographic Atrophy Secondary to Age-Related…

By Global News Feed

CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that the SAGA study of oral gildeuretinol acetate (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) demonstrated a reduction of 0.25 sqmm/year vs. placebo (p=0.07) in the primary endpoint of GA lesion growth rate at 24 months. Gildeuretinol demonstrated a statistically significant reduction in the loss of low luminance visual acuity (LLVA) at 24 months (p=0.03). Gildeuretinol showed a favorable safety profile consistent with other studies of gildeuretinol in Stargardt disease. The topline results will be presented as a late breaker at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) during Retina Subspecialty Day on Friday, October 18, in Chicago.

See more here:
Alkeus Pharmaceuticals Announces Results from the SAGA Study of Oral Gildeuretinol in Patients with Geographic Atrophy Secondary to Age-Related...

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer’s Disease Trial Demonstrating Correlation between EMACC and…

By Global News Feed

BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, today announced that results of additional analysis of blinded data from its AD02 Phase II Alzheimer's Disease (AD) trial demonstrated  exceptional performance of the novel cognitive measure EMACC, as well as highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the accepted endpoint for AD trials.

Read more:
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and...

Elicio Therapeutics Reports Inducement Grants

By Global News Feed

BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on September 16, 2024, Elicio granted an aggregate of 4,800 inducement stock options to a new employee, as an inducement material to the individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.

See the article here:
Elicio Therapeutics Reports Inducement Grants

Foxo Technologies, Inc., Completes the Acquisition of Revenue Generating Operations From Rennova Health, Inc.

By Global News Feed

Strategic Acquisitions Expected to Generate Over $20M in Annual Revenue, Positioning FOXO for Accelerated Growth Strategic Acquisitions Expected to Generate Over $20M in Annual Revenue, Positioning FOXO for Accelerated Growth

See the original post here:
Foxo Technologies, Inc., Completes the Acquisition of Revenue Generating Operations From Rennova Health, Inc.

Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection

By Global News Feed

Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform Assessment by specialist AI team from “PersonalAIze” Highlights the Strength, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform

Read more here:
Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection

Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of…

By Global News Feed

-Capricor to Receive $15 Million Equity Investment at a 20% Premium, as well as $20 Million Upfront Payment upon Signing Definitive Agreement with up to $715 Million in Potential Milestones and a Double-Digit Percentage of Product Revenue-

Read this article:
Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of...

ADIA Nutrition Stakes Claim in $6.7B Industry with Strategic Trademark Expansion

By Global News Feed

WINTER PARK, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADIA Nutrition Inc. (OTC Pink: ADIA) has announced the hiring of a prominent Winter Springs law firm to fortify its intellectual property holdings, specifically for its flagship product line under the "Biolete" brand. This strategic move aims to safeguard ADIA's intellectual property in the rapidly expanding markets for high-protein and mushroom-infused coffee products.

Read the original post:
ADIA Nutrition Stakes Claim in $6.7B Industry with Strategic Trademark Expansion

Impact BioMedical Inc. Announces the Closing of its Initial Public Offering

By Global News Feed

NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) --  Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness, today announced the closing of its previously announced initial public offering of 1,500,000 shares of its common stock at a public offering price of $3.00 per share. The shares began trading on the NYSE American Market on September 16, 2024, under the ticker symbol “IBO”.

Read more from the original source:
Impact BioMedical Inc. Announces the Closing of its Initial Public Offering

→←